Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
Apr 2, 2021Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)Nationwide availability gives healthcare providers and patients a new treatment option
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today...
Mar 29, 2021Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for RELUGOLIX for the Treatment of Advanced Prostate Cancer•If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in Europe
BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines...
Feb 17, 2021Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline
NEW YORK, LONDON, February 17, 2021 (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of...
Feb 16, 2021•Six women reflect on their period experiences and journeys to self-advocacy in new video series
RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) — HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences...
Jan 5, 2021Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™...